The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.
The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.
The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The award is one of 121 for projects in New York City this year, totaling $64.8 million.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Celmatix's Fertilome test aims to give women genetic insight into their fertility.
Trial studying the use of next-generation sequencing-based pre-implantation genetic screening has its first birth, the Guardian reports.
Loci identified in a genome-wide association study of women with spontaneous fraternal twin birth offers clues to the hormonal processes behind this propensity.
The test uses Illumina arrays to measure genome-wide sperm DNA methylation patterns in order to predict male fertility status and resulting embryo quality.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.